Irritable Bowel Syndrome - Pipeline Review, H1 2020

May 2020 | 160 pages | ID: ICB64AA3393EN
Global Markets Direct

Abstracts

Irritable Bowel Syndrome - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome – Pipeline Review, H1 2020, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 5, 2, 10, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Irritable Bowel Syndrome - Overview
Irritable Bowel Syndrome - Therapeutics Development
Irritable Bowel Syndrome - Therapeutics Assessment
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
Irritable Bowel Syndrome - Drug Profiles
Irritable Bowel Syndrome - Dormant Projects
Irritable Bowel Syndrome - Discontinued Products
Irritable Bowel Syndrome - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Irritable Bowel Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H1 2020
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2020
Irritable Bowel Syndrome - Pipeline by AsiaBiome, H1 2020
Irritable Bowel Syndrome - Pipeline by Assembly Biosciences Inc, H1 2020
Irritable Bowel Syndrome - Pipeline by Axim Biotechnologies Inc, H1 2020
Irritable Bowel Syndrome - Dormant Projects, H1 2020
Irritable Bowel Syndrome - Dormant Projects, H1 2020 (Contd..1), H1 2020
Irritable Bowel Syndrome - Dormant Projects, H1 2020 (Contd..2), H1 2020
Irritable Bowel Syndrome - Dormant Projects, H1 2020 (Contd..3), H1 2020
Irritable Bowel Syndrome - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Irritable Bowel Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
Allergan Plc
AsiaBiome
Assembly Biosciences Inc
Axim Biotechnologies Inc
Bausch Health Companies Inc
Biomica
Boston Pharmaceuticals Inc
CB2 Therapeutics Inc
CinRx Pharma LLC
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co Ltd
Eisai Co Ltd
Exeliom Biosciences SAS
GEXVal Inc
ImmuneBiotech AB
Ironwood Pharmaceuticals Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Merck & Co Inc
Metacrine Inc
MGC Pharmaceuticals Ltd
Napo Pharmaceuticals Inc
Novome Biotechnologies Inc
Oncocross Co Ltd
Orphomed Inc
Oxford Cannabinoid Technologies Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
Renexxion LLC
Sentia Medical Sciences Inc
Serentrix LLC
Synthetic Biologics Inc
Velicept Therapeutics Inc
Vitality Biopharma Inc
Zhiyi Pharmaceuticals Inc